Perrigo`s Generic Brinzolamide Receives Approval in the U.S.
ALLEGAN, Mich., Oct. 13, 2023 /PRNewswire/ -- Padagis today announced the launch of Brinzolamide Ophthalmic Suspension with Competitive Generic Therapy (CGT) exclusivity (generic equivalent to the Reference Listed Drug Azopt® Ophthalmic Suspension).
FDA Confirms Paragraph IV Patent Litigation for Simbrinza (Brinzolamide and Brimonidine Tartrate)
Enforcement Report - Week of January 26, 2022
Indoco Remedies NSE 0.42 % on Tuesday said Teva Pharmaceuticals has launched Brinzolamide ophthalmic suspension used in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma in the United States.
TEL AVIV & PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceuticals USA, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd.(NYSE and TASE: TEVA), today announced its launch of the first available generic version of AZOPT® (brinzolamide ophthalmic suspension) 1%, approved by the US Food and Drug Administration to treat high pressure inside the eye due to ocular hypertension and open-angle glaucoma. Brinzolamide ophthalmic suspension 1% works by decreasing the amount of fluid within the eye.